Physician profile
Gerald S Witherell
NPI 1114970126
$1,701.87
in general payments reported to CMS, 2019-2025
14 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $148 · 2023: $423 · 2024: $601 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $529.35 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $436.78 | 2023-2025 | Repatha, Evenity, Otezla |
| Novo Nordisk INC | $206.80 | 2023-2025 | Wegovy, Ozempic |
| Phathom Pharmaceuticals, INC. | $124.74 | 2024 | Voquezna |
| Eisai INC. | $77.53 | 2024 | |
| Abbvie INC. | $60.24 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $53.30 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $49.47 | 2025 | Breztri |
| Antares Pharma, INC. | $41.27 | 2024-2025 | Xyosted |
| Dexcom, INC. | $34.55 | 2023-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $33.93 | 2025 | Zepbound, Mounjaro |
| Pfizer INC. | $19.70 | 2025 | |
| Esperion Therapeutics, INC. | $17.65 | 2025 | Nexletol |
| Tolmar, INC. | $16.56 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Witherell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.